Cubist Systematic Strategies’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-7,321
Closed -$357K – 3302
2024
Q3
$357K Sell
7,321
-51,842
-88% -$2.76M ﹤0.01% 2350
2024
Q2
$2.62M Buy
+59,163
New +$2.73M 0.02% 1158
2024
Q1
– Sell
-4,960
Closed -$298K – 4036
2023
Q4
$298K Buy
4,960
+850
+21% +$53.9K ﹤0.01% 2795
2023
Q3
$276K Sell
4,110
-137,230
-97% -$9.53M ﹤0.01% 2636
2023
Q2
$9.76M Buy
+141,340
New +$9.24M 0.06% 444
2023
Q1
– Sell
-63,387
Closed -$3.16M – 4193
2022
Q4
$3.16M Buy
63,387
+52,687
+492% +$2.55M 0.02% 1433
2022
Q3
$437K Sell
10,700
-69,009
-87% -$3.24M ﹤0.01% 3269
2022
Q2
$4.38M Buy
79,709
+27,579
+53% +$1.16M 0.03% 1111
2022
Q1
$1.89M Buy
52,130
+21,530
+70% +$851K 0.02% 1525
2021
Q4
$1.43M Sell
30,600
-24,583
-45% -$1.25M 0.01% 1644
2021
Q3
$2.79M Sell
55,183
-32,275
-37% -$1.34M 0.04% 798
2021
Q2
$3.59M Buy
+87,458
New +$2.97M 0.04% 736
2021
Q1
– Sell
-9,639
Closed -$271K – 2906
2020
Q4
$271K Buy
9,639
+1,486
+18% +$42.8K ﹤0.01% 2088
2020
Q3
$252K Buy
8,153
+7,974
+4,455% +$268K ﹤0.01% 2042
2020
Q2
$8K Buy
+179
New +$6.99K ﹤0.01% 2346

Other funds holding LEGN

Cubist Systematic Strategies's LEGN Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Legend Biotech (LEGN) in Q4 2024, closing a stake of 7,321 shares — an estimated $357K sold.

Cubist Systematic Strategies first reported a position in LEGN in Q2 2020 and held it in 15 quarters. The position peaked at $9.76M in Q2 2023. 211 funds tracked by Wall St. Rank hold LEGN as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Legend Biotech position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 7,321 Legend Biotech shares in Q4 2024, an estimated $357K.
  • Cubist Systematic Strategies first reported a position in Legend Biotech in Q2 2020 and held it in 15 quarters.
  • Cubist Systematic Strategies's Legend Biotech position peaked at $9.76M in Q2 2023.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.